MAPT and tauopathy: These findings suggest that SGC707 effectively reduces tau hyperphosphorylation in PS19 tauopathy mice brains by decreasing H4R3me2a levels at the MIR448 promoter, subsequently suppressing miR‐448‐3p expression, thereby upregulating its target gene IGF1R and activating the PI3K/AKT/GSK3β signaling pathway.